Plus Therapeutics

Austin,  TX 
United States
https://PlusTherapeutics.com

• Booth: 8045

Plus Therapeutics invites you to learn more about our targeted radiotherapeutics being evaluated in clinical trials (Phase 1 & 2) for CNS cancers.

Plus Therapeutics, Inc. (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM),  leptomeningeal metastases (LM), and pediatric brain cancer (PBC). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

Brands: Plus Therapeutics, ReSPECT Clinical Trials, rhenium Re186 obisbemeda

 Videos

 Press Releases

• Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases (Mar 15, 2023)
  Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

• Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma (Mar 15, 2023)
  Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

 Products